Russell Investments Group
CLDX icon

Russell Investments Group’s Celldex Therapeutics CLDX Stock Holding History

Russell Investments Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.74M Buy
100,452
+91,961
+1,083% +$2.97M ﹤0.01% 1697
2026
Q1 		$269K Buy
8,491
+1,349
+19% +$36.8K ﹤0.01% 2748
2025
Q4 		$194K Sell
7,142
-220
-3% -$5.79K ﹤0.01% 2854
2025
Q3 		$190K Buy
7,362
+5,047
+218% +$117K ﹤0.01% 2830
2025
Q2 		$47.1K Buy
2,315
+501
+28% +$9.75K ﹤0.01% 2996
2025
Q1 		$32.9K Buy
1,814
+9
+0.5% +$201 ﹤0.01% 3001
2024
Q4 		$45.6K Buy
1,805
+37
+2% +$1K ﹤0.01% 2846
2024
Q3 		$60.1K Sell
1,768
-2,280
-56% -$86.9K ﹤0.01% 2757
2024
Q2 		$150K Buy
4,048
+4,019
+13,859% +$152K ﹤0.01% 2545
2024
Q1 		$1.22K Buy
+29
New +$1.19K ﹤0.01% 3119
2018
Q3 		– Sell
-753
Closed -$6K – 2954
2018
Q2 		$6K Sell
753
-1,739
-70% -$23.2K ﹤0.01% 2887
2018
Q1 		$87K Sell
2,492
-2,595
-51% -$101K ﹤0.01% 2768
2017
Q4 		$224K Sell
5,087
-18,414
-78% -$789K ﹤0.01% 2644
2017
Q3 		$1.01M Buy
23,501
+20,709
+742% +$776K ﹤0.01% 2144
2017
Q2 		$103K Sell
2,792
-1,430
-34% -$63.2K ﹤0.01% 2800
2017
Q1 		$229K Sell
4,222
-1,855
-31% -$96.6K ﹤0.01% 2668
2016
Q4 		$325K Buy
+6,077
New +$346K ﹤0.01% 2593

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Russell Investments Group's CLDX Position: Q2 2026 in Review

Russell Investments Group increased its Celldex Therapeutics (CLDX) stake by 1,083% in Q2 2026, buying an estimated $2.97M and bringing the position to 100,452 shares worth $3.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1697.

Russell Investments Group first reported a position in CLDX in Q4 2016 and has held it in 17 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Russell Investments Group held 100,452 shares of Celldex Therapeutics worth $3.74M as of Q2 2026.
  • Russell Investments Group bought 91,961 Celldex Therapeutics shares in Q2 2026, an estimated $2.97M.
  • Celldex Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #1697 holding.
  • Russell Investments Group first reported a position in Celldex Therapeutics in Q4 2016 and has held it in 17 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.